NCT05807880 2026-01-23
ALTER-HN005
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT06943820 2025-06-03
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT04974398 2025-04-13
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Akeso
Phase 3 Active not recruiting
NCT06081673 2023-10-13
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Recruiting
NCT06062563 2023-10-02
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase NA Unknown
NCT05783921 2023-07-28
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT05563480 2022-12-01
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04952493 2022-01-28
Anlotinib or Penpulimab in Combination With RAI for DTC
Peking Union Medical College Hospital
Phase 2 Unknown